NASDAQ:NBIX

Neurocrine Biosciences (NBIX) Stock Forecast, Price & News

$113.68

-0.06 (-0.05%)

(As of 09/25/2023 ET)

Compare

Today's Range: $112.90
▼
$114.62
50-Day Range: $97.20
▼
$117.10
52-Week Range: $89.04
▼
$129.29

Volume: 427,899 shs
Average Volume: 763,715 shs
Market Capitalization: $11.10 billion

P/E Ratio: 65.71
Dividend Yield: N/A
Price Target: $128.52

Neurocrine Biosciences MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.76 Rating Score
Upside/Downside: 13.1% Upside
$128.52 Price Target
Short Interest: Healthy
2.07% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -2.61
Upright™ Environmental Score
News Sentiment: 0.90
Based on 11 Articles This Week
Insider Trading: Selling Shares
$3.24 M Sold Last Quarter
Proj. Earnings Growth: 121.36%
From $2.20 to $4.87 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.80 out of 5 stars

Medical Sector

64th out of 962 stocks

Biological Products, Except Diagnostic Industry

7th out of 161 stocks

3.4

Analyst's Opinion

Consensus Rating
Neurocrine Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.76, and is based on 16 buy ratings, 5 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $128.52, Neurocrine Biosciences has a forecasted upside of 13.1% from its current price of $113.68.
Amount of Analyst Coverage
Neurocrine Biosciences has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
2.07% of the outstanding shares of Neurocrine Biosciences have been sold short.
Short Interest Ratio / Days to Cover
Neurocrine Biosciences has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Neurocrine Biosciences has recently increased by 3.59%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Neurocrine Biosciences does not currently pay a dividend.
Dividend Growth
Neurocrine Biosciences does not have a long track record of dividend growth.

2.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Neurocrine Biosciences has received a 24.32% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Valbenazine", "Elagolix", and "Opicapone" products. See details.
Environmental Sustainability
The Environmental Impact score for Neurocrine Biosciences is -2.61.

3.3

News and Social Media Coverage

News Sentiment
Neurocrine Biosciences has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 11 news articles for Neurocrine Biosciences this week, compared to 6 articles on an average week.
Search Interest
Only 6 people have searched for NBIX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
10 people have added Neurocrine Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 233% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Neurocrine Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,238,890.00 in company stock.
Percentage Held by Insiders
Only 4.60% of the stock of Neurocrine Biosciences is held by insiders.
Percentage Held by Institutions
93.54% of the stock of Neurocrine Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Neurocrine Biosciences are expected to grow by 121.36% in the coming year, from $2.20 to $4.87 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Neurocrine Biosciences is 65.71, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 123.24.
Price to Earnings Ratio vs. Sector
The P/E ratio of Neurocrine Biosciences is 65.71, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 147.82.
Price to Earnings Growth Ratio
Neurocrine Biosciences has a PEG Ratio of 1.12. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Neurocrine Biosciences has a P/B Ratio of 6.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Neurocrine Biosciences (NASDAQ:NBIX) Stock

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its products include INGREZZA and DYSVAL, for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, used as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women, as well as ALKINDI SPRINKLE, for the treatment of pediatric adrenal insufficiency. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-1117568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; Sentia Medical Sciences Inc.; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

NBIX Price History

30 days | 90 days | 365 days | Advanced Chart

NBIX Stock News Headlines

September 24, 2023 | americanbankingnews.com

Neurocrine Biosciences (NASDAQ:NBIX) Rating Increased to Strong-Buy at StockNews.com

September 23, 2023 | americanbankingnews.com

Barclays Increases Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $134.00

September 26, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

September 21, 2023 | markets.businessinsider.com

Promising CAHtalyst Study Results and Anticipated Crinecerfont Uptake Drive Analyst’s ‘Buy’ Rating for Neurocrine

September 21, 2023 | finance.yahoo.com

Neurocrine Biosciences Presents Post Hoc Data Analysis in Congenital Adrenal Hyperplasia at ESPE 2023

September 16, 2023 | americanbankingnews.com

Neurocrine Biosciences (NASDAQ:NBIX) Rating Lowered to Buy at StockNews.com

September 16, 2023 | americanbankingnews.com

Wedbush Analysts Boost Earnings Estimates for Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

September 16, 2023 | americanbankingnews.com

Analysts Set Expectations for Neurocrine Biosciences, Inc.'s Q3 2023 Earnings (NASDAQ:NBIX)

September 26, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

September 14, 2023 | finance.yahoo.com

Director Gary Lyons Sells 5,000 Shares of Neurocrine Biosciences Inc (NBIX)

September 14, 2023 | markets.businessinsider.com

Neurocrine : FDA Accepts NDA For Ingrezza Oral Granules Sprinkle Formulation

September 14, 2023 | finance.yahoo.com

Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Application for INGREZZA® (valbenazine) Oral Granules Sprinkle Formulation

September 13, 2023 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Neurocrine (NBIX), HCA Healthcare (HCA)

September 13, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Its Buy Rating for Neurocrine (NBIX)

September 12, 2023 | markets.businessinsider.com

Neurocrine (NBIX) Receives a Buy from Goldman Sachs

September 12, 2023 | msn.com

What's Going On With Neurocrine Biosciences Stock Today?

September 12, 2023 | finance.yahoo.com

Neurocrine Biosciences Inc's Meteoric Rise: Unpacking the 22% Surge in Just 3 Months

September 12, 2023 | finance.yahoo.com

Can Neurocrine Erase Its Recent Setbacks With This Jump To An Eight-Month High?

September 12, 2023 | markets.businessinsider.com

Neurocrine Biosciences Reports Positive Top-line Data From Phase 3 Study Of Crinecerfont

September 12, 2023 | finance.yahoo.com

Neurocrine Biosciences Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH)

September 11, 2023 | finance.yahoo.com

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults

August 31, 2023 | finance.yahoo.com

Neurocrine Biosciences to Present at Upcoming Investor Conferences in September

August 29, 2023 | finance.yahoo.com

Neurocrine Biosciences Presents Data at MDS International Congress of Parkinson's Disease and Movement Disorders® Demonstrating Comparable Improvement Over Time in Tardive Dyskinesia Severity and Impact Following Treatment With INGREZZA® (valbenazine) Capsules

August 28, 2023 | markets.businessinsider.com

Neurocrine Reveals New Data On Ingrezza With Improvements In HD Chorea In Huntington's Disease

August 28, 2023 | finance.yahoo.com

Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Capsules Data Demonstrating Early and Sustained Improvements in Chorea Associated With Huntington's Disease

August 25, 2023 | msn.com

Neurocrine Needs A Meaningful Clinical Win To Break Out, And Crinecerfont Could Do It

August 22, 2023 | msn.com

Cantor Fitzgerald Reiterates Neurocrine Biosciences (NBIX) Overweight Recommendation

See More Headlines

Receive NBIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter.

NBIX Company Calendar

Last Earnings: 8/01/2023
Today: 9/25/2023
Next Earnings (Estimated): 11/07/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:NBIX
CUSIP: 64125C10
CIK: 914475
Web: www.neurocrine.com
Phone: (858) 617-7600
Fax: 858-617-7602
Employees: 1,200
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $128.52
High Stock Price Forecast: $154.00
Low Stock Price Forecast: $95.00
Forecasted Upside/Downside: +13.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.76
Research Coverage: 21 Analysts

Profitability

EPS (Most Recent Fiscal Year): $1.73
Trailing P/E Ratio: 65.71
Forward P/E Ratio: 51.67
P/E Growth: 1.12
Net Income: $154.50 million
Net Margins: 10.54%
Pretax Margin: 13.99%
Return on Equity: 10.39%
Return on Assets: 7.44%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.57
Quick Ratio: 2.51

Sales & Book Value

Annual Sales: $1.49 billion
Price / Sales: 7.46
Cash Flow: $1.78 per share
Price / Cash Flow: 63.83
Book Value: $17.76 per share
Price / Book: 6.40

Miscellaneous

Outstanding Shares: 97,650,000
Free Float: 93,160,000
Market Cap: $11.10 billion
Optionable: Optionable
Beta: 0.46

10 Best Stocks to Own in 2023

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Kevin C. Gorman Ph.D. (Age 65)
CEO & Director
Comp: $1.9M

Mr. Matthew C. Abernethy (Age 43)
Chief Financial Officer
Comp: $1.04M

Mr. Darin M. Lippoldt Esq. (Age 57)
Chief Legal Officer & Corp. Sec.
Comp: $921.01k

Mr. Kyle W. Gano Ph.D. (Age 50)
Chief Bus. Devel. and Strategy Officer
Comp: $921.52k

Dr. Eiry Wyn Roberts M.D. (Age 59)
Chief Medical Officer
Comp: $1.04M

Dr. Jude Onyia Ph.D. (Age 59)
Chief Scientific Officer

Jane Sorensen
Head of Investor Relations

Ms. Julie S. Cooke (Age 57)
Chief HR Officer

Mr. Eric S. Benevich (Age 58)
Chief Commercial Officer

Mr. David Warren Boyer (Age 44)
Chief Corp. Affairs Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NBIX Stock - Frequently Asked Questions

Should I buy or sell Neurocrine Biosciences stock right now?: 21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last twelve months. There are currently 5 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NBIX shares.
View NBIX analyst ratings or view top-rated stocks.
What is Neurocrine Biosciences' stock price forecast for 2023?: 21 brokers have issued 1 year target prices for Neurocrine Biosciences' shares. Their NBIX share price forecasts range from $95.00 to $154.00. On average, they predict the company's stock price to reach $128.52 in the next twelve months. This suggests a possible upside of 13.1% from the stock's current price.
View analysts price targets for NBIX or view top-rated stocks among Wall Street analysts.
How have NBIX shares performed in 2023?: Neurocrine Biosciences' stock was trading at $119.44 on January 1st, 2023. Since then, NBIX stock has decreased by 4.8% and is now trading at $113.68.
View the best growth stocks for 2023 here.
When is Neurocrine Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our NBIX earnings forecast.
How were Neurocrine Biosciences' earnings last quarter?: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) released its earnings results on Tuesday, August, 1st. The company reported $0.95 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.18. The firm had revenue of $452.70 million for the quarter, compared to analyst estimates of $448.29 million. Neurocrine Biosciences had a net margin of 10.54% and a trailing twelve-month return on equity of 10.39%.
What ETFs hold Neurocrine Biosciences' stock?: ETFs with the largest weight of Neurocrine Biosciences (NASDAQ:NBIX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Biotechnology & Genome ETF (PBE), Goldman Sachs Future Health Care Equity ETF (GDOC), Invesco S&P MidCap Momentum ETF (XMMO), Virtus LifeSci Biotech Products ETF (BBP), Invesco S&P MidCap 400 Pure Growth ETF (RFG) and SPDR S&P Biotech ETF (XBI).
What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO?: 11 employees have rated Neurocrine Biosciences Chief Executive Officer Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among the company's employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Neurocrine Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), Walt Disney (DIS), Tesla (TSLA), Block (SQ) and Salesforce (CRM).
What is Neurocrine Biosciences' stock symbol?: Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."
Who are Neurocrine Biosciences' major shareholders?: Neurocrine Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (13.81%), State Street Corp (4.05%), Bellevue Group AG (2.68%), Renaissance Technologies LLC (1.68%), Bank of New York Mellon Corp (1.63%) and Geode Capital Management LLC (1.56%). Insiders that own company stock include Darin Lippoldt, David W Boyer, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Ingrid Delaet, Jude Onyia, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Neurocrine Biosciences Inc, Richard F Pops, Stephen A Sherwin and William H Rastetter.
View institutional ownership trends.
How do I buy shares of Neurocrine Biosciences?: Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Neurocrine Biosciences' stock price today?: One share of NBIX stock can currently be purchased for approximately $113.68.
How much money does Neurocrine Biosciences make?: Neurocrine Biosciences (NASDAQ:NBIX) has a market capitalization of $11.10 billion and generates $1.49 billion in revenue each year. The company earns $154.50 million in net income (profit) each year or $1.73 on an earnings per share basis.
How many employees does Neurocrine Biosciences have?: The company employs 1,200 workers across the globe.
How can I contact Neurocrine Biosciences?: Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The official website for the company is www.neurocrine.com. The company can be reached via phone at (858) 617-7600, via email at ir@neurocrine.com, or via fax at 858-617-7602.

This page (NASDAQ:NBIX) was last updated on 9/26/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Neurocrine Biosciences (NBIX) Stock Forecast, Price & News

Neurocrine Biosciences MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Neurocrine Biosciences (NASDAQ:NBIX) Stock

NBIX Price History

NBIX Stock News Headlines

NBIX Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

NBIX Stock - Frequently Asked Questions

Overall MarketRank^™